These ECM molecules have a critical role in tumorigenesis and angiogenesis via HAS2 turnover [76], and they are currently under investigation for stopping neoangiogenesis [77]; this finding can be a promising target for controlling the HA-derived vessel sprouting within the cancer stroma. This evidence concerns the gene HAS2 and cancer.